EXOZ (invizyne.com) Market Value to Book Value Ratio

Official company branding of Invizyne Technologies (EXOZ)

eXoZymes Inc (EXOZ) monetizes its innovative SimpleCell system, generating profit through royalties and direct agreements with industry behemoths. The business model is based on granting cell-free compound synthesis rights to external partners. The startup is currently actively forming scientific and technical alliances to verify its developments, with the indicator standing at 9.82. This chart of the company's current market value is available on the GURU.Markets platform.

EXOZ Invizyne: Market Value to Book Value in the range 02/13/2025 - 10/28/2026

Financial and market metric breakdowns for Invizyne Technologies (EXOZ)

- price and consensus price forecast:
Stock Quotes eXoZymes Inc|EXOZ - Forecast Levels Chart
- market capitalization data:
Market Value Invizyne Technologies, Inc.|EXOZ - Full Business Value
- book capitalization data:
Book Value per Share eXoZymes|EXOZ - Accounting Value of Company|Market Capitalization to Book Value Ratio invizyne.com|EXOZ - Company Total Assets
- debt and liquidity data:
Debt to Equity eXoZymes Inc|EXOZ - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Invizyne Technologies, Inc.|EXOZ - Company Total Debt|Debts to Book Capitalization Invizyne Technologies, Inc.
Initial company analysis:eXoZymes Inc - EXOZ
Original product of Invizyne Technologies, Inc.

This ratio determines the premium or discount of a business's market value relative to its net assets, revealing the extent to which fundamental indicators are overvalued. Analyzing the ratio of current market capitalization to its balance sheet allows for an assessment of how investors are actually capitalizing the strategic alliances of eXoZymes Inc (EXOZ) regarding cell-free enzyme synthesis and production cost reductions compared to the actual value of the company's resources.

Main competitors

Market Cap to Net Assets Ratio Haleon plc (HLN)|KVUE (kenvue.com) - Market Capitalization to Net Assets|Market Value to Book Value Ratio Verona Pharma VRNA|Market Capitalization to Net Assets Jyong Biotech Limited|Ligand Pharma (LGND) - Market Capitalization to Book Value Ratio|Market Value to Book Value Amneal Corp (AMRX)|Market Capitalization to Book Value Ratio PRGO (Perrigo Company plc)|alvotech.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Liquidia (LQDA)|GLPG: Market Value to Book Value|ANIP (ANI Pharma) - Market Value to Book Value Ratio|Afrezza (MNKD) - Market Cap to Net Assets Ratio|AMPH (Amphastar Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pacira.com (PCRX)|ARS Pharmaceuticals, Inc. (SPRY) - Market Cap to Net Assets Ratio|Market Value to Book Value TBPH (Theravance Biopharma Inc)|AQST: Market Value to Book Value Ratio|SCPH - Market-to-Book Ratio|Market Cap to Net Assets Ratio Tectonic TECX|TNXP - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio sxtchina.com SXTC|Eupraxia Pharmaceuticals Inc. (EPRX) - Market Value to Book Value|Market Capitalization to Book Value Ratio BHST (BioHarvest)|Market-to-Book Ratio ORMP|Entera Bio Ltd. (ENTX) - Market Value to Book Value Ratio|Market Value to Book Value ipatherapeutics.com (HYFT)|ABVC: Market Capitalization to Book Value Ratio|CPIX - Market-to-Book Ratio|Quantum BioPharma Limited (QNTM) - Market Cap to Net Assets Ratio|FGEN: Capitalization to Book Value Ratio|Market Value to Book Value Ratio TELO|Market-to-Book Ratio Rani Therapeutics Holdings, Inc.|Market Cap to Net Assets Ratio Synergy CHC Corp. SNYR|Market Capitalization to Net Assets Rallybio Corp. (RLYB)|Lexaria Bioscience - Market Cap to Net Assets Ratio|Market-to-Book Ratio PULM (Pulmatrix Corporation)|Pheton Holdings - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Aptorum Group Ltd APM|LYRA (Lyra Therapeutics) - Market Capitalization to Book Value Ratio|IBO: Market-to-Book Ratio|tnfpharma.com - Market Value to Book Value Ratio|Market Capitalization to Book Value cbdMD|PRFX - Market Cap to Net Assets Ratio|Market Value to Book Value Auris Medical|LIPO (Lipella Pharmaceuticals, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value OPTN (OptiNose Inc)|PIRS - Market Value to Book Value Ratio|Capitalization to Book Value Ratio Procaps Group Corp PROC|PTPI: Market Capitalization to Book Value Ratio|QLI - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio SLRN|Market-to-Book Ratio TFF Pharmaceuticals Inc.